Table 3. Minimum inhibitory concentration (MIC) of AMPs and amikacin (AMN) against E. coli isolates.
| E. coli isolates | Antimicrobial agent MIC (mg/L) | Resistance phenotype | |||
|---|---|---|---|---|---|
| HNP-1 | hBD-1 | hBD-3 | AMN | ||
| EC-1 | 32 | >64 | 8 | 4 | AMP, AMC, CFX, IMP, CFS, GEN, LVX, CHL |
| EC-2 | 16 | >64 | 4 | 2 | AMP, AMC, CFX |
| EC-3 | 32 | >64 | 4 | 4 | AMP, AMC, CFX, IMP, LVX, CHL |
| EC-4 | 16 | >64 | 4 | 4 | AMP, CFX, CHL |
| EC-5 | 8 | 16 | 0.5 | 4 | AMP, AMC, CFX, IMP, CHL |
| EC-6 | 4 | 32 | 1 | 1 | AMP, CHL |
| EC-7 | 4 | >64 | 4 | 4 | AMP, CHL |
| EC-8 | 16 | 32 | 8 | 4 | AMP, AMC, CFX, GEN, CHL |
| EC-9 | 8 | 32 | 16 | 4 | AMP, CHL |
| EC-10 | 32 | 8 | 8 | 4 | AMP, AMC, CFX, CHL |
| EC-11 | 32 | 16 | 4 | 2 | AMP |
| EC-12 | 32 | >64 | 2 | 1 | AMP, AMC, CFX |
| EC-13 | 8 | 8 | 1 | 2 | AMP, CHL |
| EC-14 | 4 | 32 | 2 | 4 | AMP, AMC, CFX, |
| EC-15 | 2 | >64 | 4 | 4 | AMP, AMC, CFX, LVX, CHL |
| EC-16 | 4 | 32 | 8 | 2 | AMP, CHL |
| EC-17 | 4 | 16 | 4 | 4 | AMP, AMC, CFX, GEN, CHL |
| EC-18 | 8 | 8 | 8 | 2 | AMP, CHL |
| EC-19 | 16 | 32 | 8 | 1 | AMP, AMC, CFX, CHL |
| EC-20 | 32 | 32 | 4 | 1 | AMP, CHL |
| EC-21 | 32 | >64 | 8 | 2 | AMP, AMC, CFX, IMP, LVX, CHL |
| EC-22 | 16 | 32 | 8 | 4 | AMP |
| EC-23 | 8 | >64 | 8 | 1 | AMP, CFX, CHL |
| EC-24 | 4 | >64 | 8 | 2 | AMP, AMC, CFX, CHL |
Note:
AMP, ampicillin; AMC, amoxicillin-clavulanic acid; CFX, cefotaxime; IMP, imipenem; CFS, cefoperazone-sulbactam; LVX, levofloxacin; GEN, gentamicin; AMN, amikacin; CHL, chloramphenicol.